Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lysine Administration and 2-AAA Levels (Study 3)
NCT05210504Phase 1Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lysine in type 2 diabetes mellitus (T2DM), sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in Level of 13C 2-AAA in Plasma at 6 hours and Change in Level of 2-AAA in Urine at 6 hours. Started Mar 2022; status: completed.
02
Drugs
lysine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05210504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210504.